ESC 365 - When to use a pharmaco-invasive approach rather than primary PCI

ESC Professional Premium Access

When to use a pharmaco-invasive approach rather than primary PCI

Session: Personalised management after primary PCI for ST elevation myocardial infarction: unresolved issues

Topic: ST-Elevation Myocardial Infarction (STEMI)

Speaker: Professor A. Kastrati (Munich, DE)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Professor Adnan Kastrati

German Heart Center Muenchen Technical University of Munich, Munich (Germany)

11 presentations

2 followers

4 more presentations in this session

Should everyone receive complete revascularisation after primary PCI?

Speaker: Assistant Professor B. Stahli (Zurich, CH)

Should 12 months of dual antiplatelet therapy still be the default recommendation after primary PCI?

Speaker: Professor S. James (Uppsala, SE)

How useful are risk scores in determining bleeding risk and antithrombotic therapy duration after primary PCI?

Speaker: Doctor R. Colleran (Dublin 7, IE)

Personalised management after primary PCI for ST elevation myocardial infarction: unresolved issues - discussion

Access the full session

Personalised management after primary PCI for ST elevation myocardial infarction: unresolved issues

Speakers: Professor A. Kastrati, Assistant Professor B. Stahli, Professor S. James, Doctor R. Colleran

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

novartis

Explore sponsored resources